Kornimate/medical-research-clean huggingface dataset:
alemtuzumab and rituximab in the treatment of refractory autoimmune cytopenias

Conditions: Idiopathic Thrombocytopenic Purpura; Anemia, Hemolytic, Autoimmune

Summary: the purpose of this study is to determine whether the combination of low doses of alemtuzumab and rituximab are effective in the treatment of patients with autoimmune cytopenias who has failed on steroids, relapsed after steroids withdrawal or required continuous steroids treatment.

autoimmune cytopenias are a common entities with good responses to steroids therapies as first line, but there is a considerable percentage of patients who relapse, become refractory or dependant on steroids to maintain an acceptable level of hemoglobin or platelets, and the treatment becomes more difficult increasing the secondary effects. the current study evaluates the safety and efficacy of the combination of low doses of alemtuzumab (anti cd52) and rituximab (anti cd 20) as a second line treatment option for this subset of patients improving the cytopenias without increasing the adverse effects.

Eligibility criteria:
inclusion criteria: * age: \> or = 16 years * weight: more than 40 kg * autoimmune hemolytic anemia with clinical and biochemical evidence of hemolysis refractory to treatment, in relapse or steroids dependant * idiopathic thrombocytopenic purpura with platelet counts \< 50,000, refractory to treatment, in relapse or steroids dependant exclusion criteria: * current viral or bacterial infection. * positive serology for hiv, hcv, hbv.

Keywords: idiopathic thrombocytopenic purpura anemia hemolytic autoimmune alemtuzumab rituximab
turkish version of the cognitive functioning self-assessment scale

Conditions: Cognitive Impairment

Summary: self-report scales used in the assessment of cognitive functions can serve as an initial screening tool for the general population, aside from specific neuropsychiatric tests, which are more costly and time-consuming. this study is designed to examine the validity and reliability of the turkish version of the cognitive functioning self-assessment scale (cfss). permission for the study has been obtained from the developer of the scale, dr. maria antonietta annunziata. the turkish translation of the scale will be made, and approval will be obtained from the original author for the final version. subsequently, the turkish version of the cfss, the hospital anxiety and depression scale, and the cognitive failures questionnaire will be administered to participants. surveys will be completed either online via google forms or in written form. to assess the reliability of the scale, the turkish version of the cfss will be re-administered to the same participants 7-14 days later.


Eligibility criteria:
inclusion criteria: * individuals over 18 years old exclusion criteria: * taking antidepressants * having a neurological or psychiatric disease

Keywords: cognitive function self-assessment psychometrics
study of itacitinib in combination with corticosteroids for the treatment of acute gvhd

Conditions: Graft-versus-host Disease (GVHD)

Summary: to determine if itacitinib in combination with corticosteroids is safe and tolerable in patients with grade iib-ivd acute graft-versus-host disease (gvhd).


Eligibility criteria:
inclusion criteria: * have undergone first allo-hsct from any donor source (matched unrelated donor, sibling, haploidentical) using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. recipients of nonmyeloablative and myeloablative transplants are eligible. * clinically suspected grades iib to ivd acute gvhd as per modified mn-cibmtr criteria, occurring after allo-hsct with any conditioning regimen and any anti-gvhd prophylactic program. * subjects may, but are not required to, have previously received corticosteroids for acute gvhd: * evidence of myeloid engraftment. use of growth factor supplementation is allowed. exclusion criteria: * has received more than 1 hematopoietic stem cell transplantation. * has progressed on more than 2 prior treatment regimens for acute gvhd. * presence of an active uncontrolled infection. * subjects with relapsed primary disease, or subjects who have been treated for relapse after the allogeneic hematopoietic stem-cell transplantation (allo-hsct) was performed. * inadequate recovery from toxicity and/or complications from the prior allo-hsct. * any corticosteroid therapy (for indications other than gvhd) at doses \> 1 mg/kg per day methylprednisolone or equivalent within 7 days of randomization. * previously received jak inhibitor therapy for any indication.

Keywords: acute graft versus host disease
a test and treat intervention among current people who inject drugs with hcv attending needle and syringe programs

Conditions: Hepatitis C

Summary: tempo is an interventional cohort study recruiting injecting drug users attending needle and syringe programs (nsp) in australia. three hundred participants will be invited to on-site hcv testing with nsp integrated care for hcv treatment. participants will be screened for hcv using point-of-care testing and hcv positive participants will be offered treatment with sofosbuvir/velpatasvir. of those who initiate treatment, participants will receive weekly peer-based support on-treatment and return at end of treatment (etr) and 12 weeks following end of treatment (svr12) for clinical follow-up.


Eligibility criteria:
inclusion criteria participants must meet all the following inclusion criteria to be eligible to participate in this study: 1. participants have voluntarily signed the informed consent form; 2. 18 years of age or older; 3. current injecting drug use (previous month); 4. hcv rna positive participants commencing treatment must be eligible to initiate therapy with sofosbuvir/velpatasvir; and 5. in the opinion of the investigator, the participant is suitable for nsp-based hcv treatment delivery. exclusion criteria 1) for hcv rna positive participants commencing treatment: 1. any clinically significant condition or history known to contraindicate the use of sofosbuvir/velpatasvir or would not be suitable for management within a nsp-based treatment setting; 2. any contraindicated medication in the sofosbuvir/velpatasvir product information; 3. has previous hcv daa treatment experience 4. has a fibroscan score \> 12.5 kpa 5. hiv co-infection 6. hbv co-infection 7. is female and is pregnant or breastfeeding 8. is unable or unwilling to provide informed consent or abide by the requirements of the study.
treatment effects of atorvastatin on hemostasis and skin microcirculation in patients with type 1 diabetes

Conditions: Type 1 Diabetes Mellitus; Dyslipidemia

Summary: patients with type 1 diabetes are at increased risk of vascular complications both in the micro- and macrocirculation. hyperglycemia plays a major role in the development of these vascular complications, but other factors such increased platelet adhesion and aggregation, elevated levels of plasma fibrinogen, altered fibrin network structure, increased thrombin generation, dyslipidemia and endothelial dysfunction may contribute. lipid-lowering therapy with statins is effective in prevention of cardiovascular events in individuals at increased risk. statins seem to exert beneficial effects on hemostasis and vasculature that are independent of their lipid-lowering properties. the aim of the present study was to investigated the effects of intensive ldl-cholesterol-lowering therapy with atorvastatin on fibrin network permeability (primary variable) and other aspects of hemostasis in patients with type 1 diabetes and dyslipidemia. furthermore, the effects of atorvastatin therapy on skin microvascular function was also investigated.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * level of plasma ldl-cholesterol \>2.5mmol/l and/or total cholesterol \>4.5mmol/l exclusion criteria: * history of macrovascular events
single tablet regimen (str) simplification study for hiv-1 infected patients

Conditions: HIV Infections

Summary: to compare the effectiveness (efficacy, safety \& tolerability) of a single tablet regimen of efavirenz/emtricitabine/tenofovir df to subjects continuing on unmodified haart as measured by the proportion of patients who maintain viral load (hiv-1 rna) \<200 copies/ml at week 48.


Eligibility criteria:
inclusion criteria: * hiv-1 positive patients who have maintained an hiv-1 viral load \<200 copies/ml, for at least 3 months. * patients must be on their first haart or have documented viral suppression on a pi-based regimen at the time of any prior change in therapy. * haart must consist of either: 1. a pi (with or without ritonavir) + at least 2 nrtis or 2. an nnrti + at least 2 nrtis. * negative serum pregnancy test. exclusion criteria: * patients who have taken any nnrti prior to their current therapy. * patients who have taken a nrti-only therapy for greater than 7 days prior to their current therapy. * patients who are currently taking efv+ftc+tdf. * patients who have a creatinine clearance of \<60 ml/min by cockcroft-gault estimation. * patients who have experienced virologic failure with any previous arv therapy. * patients who have documented resistance to any of the study agents at any time in the past.

Keywords: hiv hiv-1 aids human immunodeficiency virus hiv-1 infection
effect of myofascial release technique in patients with unilateral cervical radiculopathy

Conditions: Cervical Radiculopathy; Cervical Radicular Pain; Cervical; Hernia; Cervical Disc Disease; Cervical Disc Herniation; Pain

Summary: the aim of the study is to investigate the effectiveness of myofascial release technique on pain, range of motion, muscle strength, functionality and quality of life in individuals diagnosed with cervical radiculopathy with unilateral arm involvement and compare this with exercise. the individuals included in the study will be randomized into two groups, 17 control and 17 study groups. sessions will be 3 days a week for 4 weeks. conventional physiotherapy and exercise program will be applied to the control group, conventional physiotherapy and myofascial release technique will be applied in the intervention group. conventional physiotherapy methods; it will include transcutaneous electrical nerve stimulation (tens), ultrasound (us), hotpack agents. exercise program; extension, right and left lateral flexion, right and left rotation exercises, chin-tuck, right and left upper trapezius muscle group stretching, neck extensor muscle group isometric strengthening exercises. myofascial release will be applied to the fingers, wrist flexor-extensor muscle groups, elbow flexor-extensor muscle groups, pectoral muscles and rotator cuff muscle groups. patients will be evaluated before and after treatment with visual analogue scale (vas), goniometric measurements, algometer, myometer, neck disability scale, "disability of arm, shoulder and hand" questionnaire (dash).


Eligibility criteria:
inclusion criteria: * getting a diagnosis of cervical radiculopathy * unilateral upper extremity symptoms at least for a month * the diagnosis is confirmed by the medical board report * being between the ages of 30-65 * voluntary acceptance to participate in the study exclusion criteria: * previous cervical surgery * previous cervical trauma * have had myofascial therapy or conventional therapy for cervical radiculopathy * long-term use of corticosteroids * congenital torticollis history * using nonsteroidal anti-inflammatory drugs for long time * migraine * cancer * tumor * osteoporosis * pregnancy

Keywords: cervical radiculopathy pain radiculopathy cervical hernia myofascial release exercise
evolutionary systems therapy for personality pathology

Conditions: Personality Disorders

Summary: evolutionary systems therapy is a new form of therapy that has been previously tested in a randomized controlled trial and in a few cases of patients diagnosed with cluster a personality disorders. the objective of the present study is to investigate the feasibility and preliminary efficacy of evolutionary systems therapy in all forms of personality disorders. the study includes three project actions: (i) a case series on adolescents with personality disorders; (ii) a case series on young adults with personality disorders; (iii) an ecological momentary assessment study to confirm the conceptualization model on all the patients.

to explore the feasibility and preliminary efficacy of evolutionary systems therapy, the present study includes three actions. in the first action investigators enroll 6 adolescents (16-19 years) with personality disorders, in the second 15 young adults (20-25 years) with personality disorders. all participants receive 6 months of psychotherapy. the two subsamples of patients (adolescents and young adults) are assessed based on the conceptualization model of evolutionary systems therapy which envisages three macro-organizations of personality (consistently with dimensional and hierarchical models such as hierarchical taxonomy of psychopathology): internalizing, externalizing, schizotypal. investigators plan to recruit patients until the size of the sub-samples is reached (15 young adults divided into 3 groups of 5 patients, each for each of the three interpersonal patterns; 6 adolescents divided into 3 groups of 2 patients, each for each of the three patterns interpersonal). in the third action, an ecological momentary assessment study will investigate the consistency over time between the conceptualization model and the experiences of the young adult patients enrolled: investigators will explore whether the hypothesized conceptualization will be confirmed by collected data on the patients' interpersonal styles.

Eligibility criteria:
inclusion criteria: * being diagnosed with personality pathology in accordance with structured clinical interview for dsm-5 - alternative model of personality disorders module i * being capable of read and sign the inform consent form exclusion criteria: * being diagnosed with schizophrenia spectrum disorders and other psychosis * being diagnosed with bipolar disorders * being diagnosed with autism spectrum disorder * being diagnosed with intellectual disability * being under any psychopharmacological or psychosocial treatment

Keywords: compassion metacognition personality disorder personality pathology evolutionary psychopathology
acute intense paraphilic desire (dsm-v) down-regulation via tavns neuro-modulation [transcutaneous afferent vagus nerve] with future operative implant consideration

Conditions: Desire; Sexual, Aversion; Paraphilia

Summary: transcutaneous afferent vagus nerve stimulation \[tavns\] is used to modulate persistent \& intense desire control amongst a specific participant group. testing center order of deliver number

tavns diagnostic spectrum testing center order of delivery 1. - addiction - opioid 2. - chronic pain - central 3. - anxiety + panic disorder 4. - mdd - major depression disorder 5. - addiction - nicotine 6. - adhd 7. - addiction - stimulant 8. - addiction - sexual + love 9. - addiction - paraphilia 10. - parkinsons 11. - immune enhancing 12. - addiction - overeating re-ordered clinical trial - nine physiologic effects of tavns stimulation have been extensively researched for over 150 years. drug-resistant depression (mdd), migraine headaches, pelvic pain modulation, facilitation of motor learning in neonates, post stroke rehabilitation and seizures are some of the conditions investigated with favorable results using tavns intervention. tavns physiologic \& mental effects have been noted to have advantageous therapeutic results on a vast diagnostic spectrum. a clinical testing program for pre- and post-test was devised as a means to identify \& measure treatment effects in specific t3, 4 and early 5 (tanner) sub-group visual stimulation. the programmatic (software) of the stimulation medium created for this study is aimed to abate the use of a phallometric device purposed to measure sexual stimulation effects on participants. great effort has been assigned for the preservation of visual data to be shared in the investigators' research centre with other researchers internationally. the participant testing platform created for this study allows for a full-proof research ethics anonymous \& confidential registry \& testing process (triple blind). aggressive optimum (supra-threshold and below-pain threshold) tavns is the therapeutic modality of choice in order to examine desire down-regulation effects using tavns. dsm-v stock participants must be sub-grouped in the paraphilic categorical structure of the dsm-v.

Eligibility criteria:
inclusion criteria: * 21 to 60 years old - heterosexual identifying as he/him exclusion criteria: * 35 to 40 age group - heterosexual identifying as he/him

Keywords: down-regulation vagus cranial nerve modulation desire control tavns [transcutaneous afferent vagus nerve stimulation]
the effectiveness of a high-protein liquid dietary supplementation

Conditions: Malnutrition; Nutritional Status; Hospital; Hand Strength; Body Mass Index; Nutrition Assessment

Summary: this study was a double-blind randomized controlled trial conducted to assess the effectiveness of high protein liquid dietary supplementation in malnourished hospitalized patients. the patients were assessed for their nutritional status based on espen 2015 criteria. patients who experienced malnutrition will be divided into 2 groups, namely the control group which was given a normal protein liquid diet, while the intervention group was given high protein liquid diet supplementation as much as 2 bottles (200 ml) per day for 7-10 days. furthermore, the nutritional status of the patient was assessed.


Eligibility criteria:
inclusion criteria: 1. subjects aged ≥ 18 years old to 60 years old 2. malnutrition hospitalized patient based on european society for clinical nutrition and metabolism (espen) 2015 criteria 3. agreed to participate exclusion criteria: 1. malignancy 2. chronic kidney disease stage iii-v 3. decompensated hepatic cirrhosis 4. allergic to milk or lactose intolerance 5. could not be randomised and participate in this study by clinical judgement

Keywords: malnutrition high-protein diet nutritional status hospitals hand strength body mass index nutrition assessment preliminary data
heart inflammation and mental stress study

Conditions: Hypertension

Summary: the aim of the study is to investigate the neural underpinnings of cardiovascular reactivity to mental stress as a function of hiv and hypertensive risk.

the main objectives of the study are to assess (1) patterns of brain activity/connectivity that confers greater cardio-autonomic/emotion regulation, (e.g., heart rate variability, blood pressure reactivity, inflammatory-immune activation, etc.), during rest, mental stress, and anger-related distress, (2) whether changes in breathing pace mitigate task-based effects on cardio-autonomic-immune regulation, and (3) whether these patterns vary as a function of hiv or pre-hypertensive (htn) status-related changes to the brain structures underlying cardioautonomic and emotion regulation.

Eligibility criteria:
inclusion criteria: 1. pre-hypertension screening. 2. hiv-antibody testing. exclusion criteria: 1. current use of anti-lipid, antihypertensive, or heart rate altering medications; 2. current or lifetime history of cardiovascular disease diagnosis or treatment including pulmonary stenosis, heart valve abnormalities and hypertension; 3. current or lifetime diagnoses of cancer, kidney/liver disease, hypertension, type 1 or type 2 diabetes; 4. history of trauma, cerebral infarction or hemorrhage; 5. current diagnosis and/or treatment for hypertension; 6. severe cognitive impairment; 7. current treatment or diagnosis of psychiatric illness; 8. metal implants or debris within the body; or pregnancy; 9. body mass index \> 35; 10. use of hormone replacement therapy; and current smoker.

Keywords: high blood pressure hiv
pancreatic surgery and risk factors

Conditions: Pancreatic Surgey; Diabetes Mellitus

Summary: the goal of this observational study is to learn about post-pancreatic surgery diabetes mellitus(pcrd).the main questions it aims to answer are: 1. what are the clinical characteristics of pcrd? 2. what are the related factors for pcrd? all patients with pancreatic surgery have been given standardized treatment fot the condition. the researchers will summarize the risk factors for pcrd from the pcrd group.

sponsors retrospectively collected data from patients with pancreatic surgery in changzheng centers between january 2017 and june 2024.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years and \<80 years, male or female; 2. patients who underwent pancreatic resection in pancreaticobiliary surgery since january 2017 3. those who have previously completed a cohort study in pancreaticobiliary surgery and signed informed consent; 4. those who have completed and banked serum specimens and pathology specimens in our hospital. - exclusion criteria: 1. age \<18 years or ≥80 years; 2. those with preoperative fasting blood glucose ≥5.8 mmol/l or hba1c ≥6.0% or a history of diabetes; 3. those with missing relevant data. -

Keywords: pancreatic surgey diabetes mellitus pcrd risk factor
actuation indicator trial in patients with copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with copd. the actuation indicator is integrated into mouthpiece of the ipratropium bromide hfa inhalation aerosol device. as part of boehringer ingelheim's program to qualify an actuation indicator for use with the ipratropium bromide hfa inhalation aerosol device, this study is intended to complement the results from the ongoing in-vitro studies.


Eligibility criteria:
inclusion criteria: 1. a diagnosis of copd based on medical history at a severity to require maintenance treatment with a bronchodilator 2. male or female patients 40 years of age or older 3. a smoking history of more than ten pack-years. a pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year 4. must be able to use the study mdi with the mouthpiece containing actuation indicator exclusion criteria: 1. significant diseases other than copd are excluded. a significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study 2. malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last three months. patients with treated basal cell carcinoma are allowed 3. history of asthma 4. significant history active alcohol or drug abuse 5. known active tuberculosis 6. known narrow-angle glaucoma 7. current significant psychiatric disorders 8. pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices or diaphragm with spermicide, or norplant®) 9. known hypersensitivity to anticholinergic drugs, any other component of the ipratropium bromide, hfa-134a or mdi components 10. previous participation in this trial 11. patients who are currently participating in another trial and/or who have received investigational drug within the past 30 days